Chk1 inhibitors tend to be more effective in cancers where the G1/S checkpoint (controlled by p53) is dysfunctional, forcing the cells to rely heavily on the S/G2 checkpoint for survival (Merry et al., 2010). The gene discussed is CHEK1; the disease is cancer.